BreMel/rGel (Targa Therapeutics)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug NameBreMel/rGel (Targa Therapeutics)
Drug Alias Nameaka scFvMel/rGel (Targa Therapeutics)ZME-018 antibody fragment/rGel (Targa Therapeutics)scFvMel/rGel (Targa Therapeutics)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsBreast NeoplasmsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesTarga Therapeutics Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTarga Therapeutics Corp
Active IndicationsN/A
Inactive IndicationsBreast NeoplasmsMelanoma

Other Information

ATC CodeN/A
Related LinksN/A